Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of…
Hypertension, or high blood pressure, is known to have a direct impact on heart attack and stroke risk — but a new study has revealed its surprising link to brain health.
In a large, randomized trial, researchers led by First Hospital…
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us